DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
43.86 USD
+0.07 (+0.16%)
43.86 USD
0 (0%)
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. Both the health and profitability get an excellent rating, making DOCS a very profitable company, without any liquidiy or solvency issues. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
DOCS had positive earnings in each of the past 5 years.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS's Return On Assets of 20.13% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Return On Equity of 23.10% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 18.16%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.61%.
The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
With an excellent Profit Margin value of 40.72%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 39.72%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DOCS has grown nicely.
The Gross Margin of DOCS (90.20%) is better than 97.14% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DOCS is creating value.
DOCS has more shares outstanding than it did 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 32.84 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a better Altman-Z score (32.84) than 97.14% of its industry peers.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 32.84 |
ROIC/WACC1.88
WACC9.67%
2.3 Liquidity
A Current Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
DOCS's Current ratio of 7.79 is amongst the best of the industry. DOCS outperforms 91.43% of its industry peers.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
The Quick ratio of DOCS (7.79) is better than 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.43% over the past year.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
Looking at the last year, DOCS shows a very strong growth in Revenue. The Revenue has grown by 20.21%.
DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
The Earnings Per Share is expected to grow by 14.75% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.49% yearly.
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.74, the valuation of DOCS can be described as expensive.
80.00% of the companies in the same industry are more expensive than DOCS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of DOCS to the average of the S&P500 Index (27.25), we can say DOCS is valued inline with the index average.
DOCS is valuated quite expensively with a Price/Forward Earnings ratio of 25.04.
DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 68.57% of the companies in the same industry.
DOCS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 25.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 74.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.46 | ||
| EV/EBITDA | 25.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.88
PEG (5Y)0.34
EPS Next 2Y11.46%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.86
+0.07 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners91.38%
Inst Owner Change-0.02%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap8.26B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.86
Price Target69.67 (58.85%)
Short Float %5.99%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-0.18%
PT rev (3m)-1.81%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0.18%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)1.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 25.04 | ||
| P/S | 13.29 | ||
| P/FCF | 26.46 | ||
| P/OCF | 25.83 | ||
| P/B | 7.54 | ||
| P/tB | 8.5 | ||
| EV/EBITDA | 25.75 |
EPS(TTM)1.64
EY3.74%
EPS(NY)1.75
Fwd EY3.99%
FCF(TTM)1.66
FCFY3.78%
OCF(TTM)1.7
OCFY3.87%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.88
PEG (5Y)0.34
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 32.84 |
F-Score9
WACC9.67%
ROIC/WACC1.88
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.72%
EBIT Next 3Y13.76%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 26.74 and the Price/Book (PB) ratio is 7.54.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.22% in the next year.